globenewswire

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of its public offering of an aggregate of 2,768,600 shares of its Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants.

SINGAPORE, June 04, 2025 (GLOBE NEWSWIRE) -- MoneyHero Limited (NASDAQ: MNY) (MoneyHero” or the “Company”), a leading personal finance aggregation and comparison platform, as well as a digital insurance brokerage provider in Greater Southeast Asia, today announced a strategic partnership with Rizal Commercial Banking Corporation (“RCBC”), a trusted leader in Philippine banking known for its customer-focused innovation and inclusive financial services, through its card servicing entity, RCBC Bankard Services Corporation (“RCBC Credit Cards”). Through this collaboration, MoneyHero will integrate RCBC’s full suite of rewards, lifestyle, travel, and premium credit card products into its digital platform, enabling Filipinos to seamlessly discover, compare, and apply for cards that suit their personal financial needs.

新加坡, June 05, 2025 (GLOBE NEWSWIRE) -- MoneyHero Limited（納斯達克：MNY）（以下簡稱「MoneyHero」或「公司」）是大東南亞領先的個人理財產品比較平台及數字保險經紀服務供應商，今日宣佈與RCBC信用卡發卡機構——菲律賓中華銀行（以下簡稱「RCBC」）達成戰略合作。RCBC是菲律賓銀行業的領導者，以其以客為本的創新服務及普惠金融服務著稱。此次合作透過RCBC服務機構RCBC Bankard Services Corporation推進。MoneyHero將全面把RCBC的獎賞、生活方式、旅遊及高端信用卡產品整合到其數字平台中，助力菲律賓消費者輕鬆探索、比較並申請最符合其個人財務需求的信用卡。

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cerevel Therapeutics Holdings, Inc. (CERE) on behalf of long-term stockholders following a class action complaint that was filed against Cerevel on April 3, 2025 with a Class Period from October 11, 2023 through August 1, 2024. Our investigation concerns whether the board of directors of Cerevel have breached their fiduciary duties to the company.

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) on behalf of Tempus stockholders. Our investigation concerns whether Tempus has violated the federal securities laws and/or engaged in other unlawful business practices.

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Sable Offshore Corp. (“Sable” or the “Company”) (NYSE:SOC). The investigation concerns whether Sable and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor (“TKI”) has been accepted for review by the China National Medical Products Administration (“NMPA”).

New briefing reveals how Trump and Musk are quietly building the most powerful artificial intelligence system in U.S. history — and why July 1 could mark a major turning point

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.


Frøya, 5 June 2025: Reference is made to the stock exchange release from Kaldvík AS (the "Company") published on 4 June 2025 regarding a contemplated private placement to raise gross proceeds of the NOK equivalent of approximately EUR 46.2 million (the "Private Placement") by the issuance of new shares in the Company (the "Offer Shares"). The Company hereby announces that it has raised approximately NOK 532 million, equivalent to approximately EUR 46.2 million, in gross proceeds through a private placement of 38,011,050 new shares (the "New Shares") at a price per share of NOK 14 (the "Offer Price"). The Private Placement took place through an accelerated bookbuilding process managed by DNB Carnegie, a part of DNB Bank ASA ("DNB Carnegie") as Sole Global Coordinator and Joint Bookrunner and Arion Banki hf ("Arion") and Nordea Bank Abp, filial i Norge ("Nordea") as Joint Bookrunners for the Private Placement (jointly, the "Managers").